Kato, Japan

Takumi Numazawa


 

Average Co-Inventor Count = 3.7

ph-index = 1

Forward Citations = 8(Granted Patents)


Location History:

  • Katoh-gun, JP (2001)
  • Kato, JP (2018)

Company Filing History:


Years Active: 2001-2018

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Takumi Numazawa: Innovator in Therapeutic Agents

Introduction

Takumi Numazawa is a prominent inventor based in Kato, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in developing therapeutic agents for various diseases. With a total of 2 patents, his work focuses on innovative solutions for inflammatory and degenerative conditions.

Latest Patents

Numazawa's latest patents include a therapeutic/preventive agent containing a coumarin derivative as an active ingredient. This method aims to prophylactically or therapeutically treat inflammatory diseases and degenerative intervertebral disk diseases. The method involves administering an effective amount of a coumarin derivative, which can be represented by a specific formula. Additionally, he has developed a therapeutic agent for intractable vasculitis, such as malignant rheumatoid arthritis, which contains a hydantoin derivative as an effective ingredient.

Career Highlights

Takumi Numazawa is associated with Nippon Zoki Pharmaceutical Co., Ltd., where he continues to innovate in the pharmaceutical industry. His work has garnered attention for its potential impact on treating complex medical conditions.

Collaborations

Numazawa collaborates with notable colleagues, including Mitsuru Naiki and Tomoyuki Okada, to advance research and development in therapeutic agents.

Conclusion

Takumi Numazawa's contributions to the field of pharmaceuticals highlight his commitment to improving treatment options for patients with challenging health conditions. His innovative patents reflect a dedication to advancing medical science and enhancing patient care.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…